🔥🐔 BizChicken 🐔🔥

Companies Similar to Bolt Biotherapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

DNAbilize

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company, developing products based on the DNAbilize technology. The company is advancing its lead drug candidate, prexigebersen, for the treatment of AML and myelodysplastic syndrome.

Tags: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, DNAbilize, Drug Development, Lymphoma, Myelodysplastic Syndrome, Oncology, Pancreatic Cancer, Prexigebersen, RNAi

Symbol: BPTH

Recent Price: $1.17

Industry: Biotechnology

CEO: Mr. Peter H. Nielsen MBA

Sector: Healthcare

Employees: 10

Address: 4710 Bellaire Boulevard, Bellaire, TX 77401

Phone: 832 742 1357

Leadership

  • Peter Nielsen, Chief Executive Officer, Chief Financial Officer
  • Ana Tari Ashizawa, PhD, MBA, Senior Vice President of Research, Development & Clinical Design
  • Anthony Price, MBA, Senior Vice President of Finance, Accounting & Administration
  • Michael Hickey, MBA, Vice President of Clinical Operations
  • Michael Roberts, Director of Manufacturing Planning & Engineering
  • Chairman of the Board,
  • President,
  • Heath Cleaver, Director
  • Paul Aubert, Director
  • Douglas P. Morris, Director
  • Aline Sherwood, Director

Last updated: 2024-12-31

BioAtla, Inc.

BioAtla, Inc. logo
Market Cap: Low
Employees: Low

BA3011

Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.

Tags: antibody-based therapeutics, biopharmaceutical, cancer, clinical stage, solid tumor

Symbol: BCAB

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Jay M. Short Ph.D.

Sector: Healthcare

Employees: 65

Address: 11085 Torreyana Road, San Diego, CA 92121

Phone: 858 558 0708

Last updated: 2024-12-31

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

BDTX-189, BDTX-1535, BDTX-4933

Black Diamond Therapeutics, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for patients with genetically defined tumors. The company focuses on creating irreversible small molecule inhibitors to target specific oncogenic proteins.

Tags: biotechnology, cancer treatment, genetically defined tumors, small molecule inhibitors

Symbol: BDTX

Recent Price: $2.15

Industry: Biotechnology

CEO: Dr. Mark A. Velleca M.D., Ph.D.

Sector: Healthcare

Employees: 54

Address: One Main Street, Cambridge, MA 02142

Phone: 617 252 0848

Leadership

  • Ali Behbahani, M.D., Co-Head of Healthcare, NEA
  • Shannon Campbell, Executive Vice President and Chief Commercial Officer, Merus
  • Kapil Dhingra, M.D., Former Head, Roche Oncology Development
  • Samarth (Sam) Kulkarni, Ph.D., CEO, CRISPR Therapeutics AG
  • Garry E. Menzel, Ph.D., Operating Partner, GHO Capital Partners LLP
  • Prakash Raman, Ph.D., CEO of InduPro, Inc.
  • Mark A. Velleca, M.D., Ph.D., CEO and Board Chair

Last updated: 2024-12-31

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

BDC-1001

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology agents that target tumor cells for immune system elimination.

Tags: HER2, biotechnology, cancer treatment, clinical-stage, immuno-oncology

Symbol: BOLT

Recent Price: $0.57

Industry: Biotechnology

CEO: Mr. William P. Quinn

Sector: Healthcare

Employees: 100

Address: 900 Chesapeake Drive, Redwood City, CA 94063

Phone: 650 665 9295

Last updated: 2024-12-31

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

IGALMI

Bio Xcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence for developing transformative medicines in neuroscience and immuno-oncology. It focuses on re-innovating existing drugs with machine learning to identify new therapeutic uses.

Tags: agitation treatment, artificial intelligence, biopharmaceutical, clinical trials, immuno-oncology, neuroscience

Symbol: BTAI

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Vimal D. Mehta Ph.D.

Sector: Healthcare

Employees: 74

Address: 555 Long Wharf Drive, New Haven, CT 06511

Phone: 475 238 6837

Last updated: 2024-12-31

Cue Biopharma, Inc.

Cue Biopharma, Inc. logo
Market Cap: Low
Employees: Lowest

CUE-101

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing biologic drugs to modulate the human immune system for treating cancers, chronic infectious diseases, and autoimmune disorders.

Tags: autoimmune disorders, biopharmaceutical, cancer, chronic diseases, immune system

Symbol: CUE

Recent Price: $1.02

Industry: Biotechnology

CEO: Mr. Daniel R. Passeri J.D., M.Sc.

Sector: Healthcare

Employees: 53

Address: 21 Erie Street, Cambridge, MA 02139

Phone: 617 949 2680

Leadership

  • Dan Passeri, Chief Executive Officer
  • Anish Suri, President and Chief Scientific Officer
  • Lucinda Warren, Chief Business Officer
  • Matteo Levisetti, Chief Medical Officer
  • Kerri-Ann Millar, Chief Financial Officer
  • Colin Sandercock, Senior Vice President and General Counsel
  • Frank Morich, M.D., Ph.D., Chairman of the Board
  • Dan Passeri, M.Sc., J.D., Chief Executive Officer
  • Peter Kiener, D.Phil.,
  • Fred Driscoll,
  • Patrick Verheyen,
  • Pamela D. Garzone, Ph.D.,

Last updated: 2024-12-31

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

DAY101

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for genetically defined cancers. Their lead product candidate is DAY101, currently in Phase II clinical trials for pediatric patients with low-grade glioma.

Tags: DAY101, Pimasertib, biopharmaceuticals, cancer therapy, clinical-stage

Symbol: DAWN

Recent Price: $12.58

Industry: Biotechnology

CEO: Dr. Jeremy Bender M.B.A., Ph.D.

Sector: Healthcare

Employees: 174

Address: 395 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 484 0899

Leadership

  • Samuel Blackman, MD, PhD, Head of R&D
  • Elly Barry, MD, Chief Medical Officer
  • Jeremy Bender, PhD, MBA, Director
  • Davy Chiodin, PharmD, Chief Development Officer
  • Adam Dubow, General Counsel
  • Lauren Merendino, MBA, Chief Commercial Officer
  • John Stubenrauch, Chief Technology Officer
  • Jaa Roberson, Chief People Officer
  • Charles N. York II, MBA, Chief Operating and Financial Officer
  • Garry Nicholson, MBA, Chair
  • Habib Dable, Director
  • Scott Garland, Director
  • Michael Gladstone, Director
  • William Grossman, MD, PhD, Director
  • Natalie Holles, Director
  • John A. Josey, PhD, MBA, Director
  • Saira Ramasastry, MS, MPhil, Director

Last updated: 2024-12-31

Immunome, Inc.

Immunome, Inc. logo
Market Cap: Medium
Employees: Low

IMM-ONC-01, IMM-BCP-01

Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics for oncology and infectious diseases, offering innovative solutions such as IMM-ONC-01 for cancer and IMM-BCP-01 for COVID-19 treatment.

Tags: antibody therapeutics, biopharmaceutical, infectious disease, oncology

Symbol: IMNM

Recent Price: $10.28

Industry: Biotechnology

CEO: Dr. Clay B. Siegall Ph.D.

Sector: Healthcare

Employees: 78

Address: 665 Stockton Drive, Exton, PA 19341

Phone: 610 321 3700

Last updated: 2024-12-31

Immuneering Corporation

Immuneering Corporation logo
Market Cap: Lowest
Employees: Low

IMM-1-104 and IMM-6-415

Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.

Tags: biopharmaceutical, cancer treatment, drug development, neuroscience, oncology

Symbol: IMRX

Recent Price: $2.25

Industry: Biotechnology

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Sector: Healthcare

Employees: 66

Address: 245 Main Street, Cambridge, MA 02142

Phone: 617 500 8080

Last updated: 2024-12-31

Immunovant, Inc.

Immunovant, Inc. logo
Market Cap: High
Employees: Low

batoclimab

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases, including batoclimab for myasthenia gravis and thyroid eye disease.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, monoclonal antibodies

Symbol: IMVT

Recent Price: $23.88

Industry: Biotechnology

CEO: Dr. Peter Salzmann M.B.A., M.D.

Sector: Healthcare

Employees: 207

Address: 320 West 37th Street, New York, NY 10018

Phone: 917 580 3099

Leadership

  • Pete Salzmann, M.D., MBA, Chief Executive Officer
  • Renee Barnett, MBA, Chief Financial Officer
  • Christine Blodgett, Senior Vice President of Human Resources
  • Andy Deig, Senior Vice President Strategic Finance
  • Michael Geffner M.D., MBA, Chief Medical Officer
  • Julie Kirschling, Senior Vice President, Program and Alliance Management
  • Mark Levine, Chief Legal Officer and Corporate Secretary
  • Bill Macias, M.D., Ph.D., Chief Medical Officer
  • Becky Merlina, Senior Vice President, Global Head of Quality
  • Jody Roth, MS, RAC, PMP, Senior Vice President, Regulatory Affairs
  • Jay S. Stout, PhD, Chief Technology Officer
  • Yan Zheng, Ph.D., Senior Vice President Biostatistics, Programming & Data Management
  • Chandra Adams, Vice President, Associate General Counsel
  • Maria Alba, M.D., Vice President of Clinical Development
  • Farah Ali, Vice President, Clinical Development
  • Jennifer Ashley, Vice President, Associate General Counsel
  • Annetta Beauregard, Vice President, Regulatory Affairs Strategy
  • Harry Berlanga, MSc., VP, CMC & Distribution Quality
  • Ranjit Deshmukh, Ph.D., Vice President of CMC and Technical Operations
  • Scott Forman, MBA, Vice President, Program Management
  • Tom Forman, MBA, Vice President, CMC Project Management
  • Ian Gourley, M.D., Vice President of Clinical Development
  • Thomas Hardy, M.D., Ph.D., Vice President of Drug Safety and Pharmacovigilance
  • Laci Hasenour, Vice President Marketing, Neurology
  • Aileen Ilaria, MBA, Vice President, Clinical Operations – Global Site Management
  • Claudia Jacobs, Ph.D., Vice President of CMC Project Management Operations and Clinical Supply
  • Jonathan Janes, MB, Vice President Clinical Development
  • Ant Kidwell, Vice President of IT and Facilities
  • Chedvi Levin-Sister, Vice President of Finance
  • Launi Masterson, Vice President of Clinical Operations
  • Andy Minke, Vice President Program Management
  • Linda McKerral, Vice President, CMC Analytical Sciences
  • Pooja Mehta, Vice President Drug Substance Tech Transfer
  • Regina Mirra, VP, Regulatory Operational Excellence
  • Jennifer Moseley, Vice President of Clinical Operations
  • Sheetal Patel M.D., MS MBA, Vice President of Clinical Development
  • Cassandra Pauyo, Vice President, Data Management
  • Rod Saponjic Ph.D., MBA, Vice President of Clinical Operations
  • Lauren Schrier, MBA, Vice President of Marketing
  • Frank Torti, M.D., Chairperson of Board of Directors
  • Andrew Fromkin, Member of Board of Directors
  • Douglas Hughes, Member of Board of Directors
  • George Migausky, Member of Board of Directors
  • Atul Pande, M.D., Member of Board of Directors
  • Eric Venker, M.D., Pharm.D., Member of Board of Directors

Last updated: 2024-12-31

PDS Biotechnology Corporation

PDS Biotechnology Corporation logo
Market Cap: Low
Employees: Lowest

PDS0101

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.

Tags: biopharmaceutical, cancer immunotherapies, clinical trials, clinical-stage, oncology, vaccines

Symbol: PDSB

Recent Price: $1.69

Industry: Biotechnology

CEO: Dr. Frank K. Bedu-Addo Ph.D.

Sector: Healthcare

Employees: 25

Address: 25B Vreeland Road, Florham Park, NJ 07932

Phone: 800 208 3343

Leadership

  • Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
  • Stephan Toutain, Chief Operating Officer
  • Lars Boesgaard, Chief Financial Officer
  • Gregory Conn, Ph.D., Chief Scientific Officer
  • Kirk Shepard, M.D., Chief Medical Officer
  • Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
  • Rory Cullinane, Vice President of Quality
  • Joe Dervan, Ph.D., Vice President of Research and Development
  • David Schaaf, M.D., Vice President of Medical Affairs
  • Sir Richard Sykes, Director
  • Ilian Iliev, Ph.D., Director
  • Gregory Freitag, J.D., CPA, Director
  • Otis W. Brawley, M.D., Director
  • Kamil Ali-Jackson, J.D., Director
  • Stephen Glover, Chairman

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

SON-1010, SON-080

Sonnet Bio Therapeutics Holdings, Inc. is a clinical stage oncology-focused biotechnology company developing biologic medicines using its human albumin binding technology. The company is based in Princeton, New Jersey, and has lead candidates such as SON-1010 for non-small cell lung cancer, and SON-080 for neuropathies.

Tags: albumin binding technology, biologic medicines, biotechnology, interleukin 12, interleukin 6, oncology

Symbol: SONN

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Pankaj Mohan Ph.D.

Sector: Healthcare

Employees: 12

Address: 100 Overlook Center, Princeton, NJ 08540

Phone: 609-375-2227

Leadership

  • Pankaj Mohan, Ph.D., Founder, CEO & Chairman
  • Jay Cross, Chief Financial Officer
  • John K. Cini, Ph.D., Chief Scientific Officer & Co-Founder
  • Susan Dexter, Chief Technical Officer
  • Richard Kenney, M.D., Chief Medical Officer
  • Albert Dyrness, Board Member
  • Nailesh Bhatt, Chief Executive Officer & Board Member
  • Raghu Rao, Board Member
  • Donald Griffith, Financial Controller
  • Lori McNeill, Board Member

Last updated: 2024-12-31

Instil Bio, Inc.

Instil Bio, Inc. logo
Market Cap: Low
Employees: Lowest

ITIL-168, ITIL-306

Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.

Tags: TIL, biopharmaceutical, cancer therapy, cell therapy, clinical-stage

Symbol: TIL

Recent Price: $18.99

Industry: Biotechnology

CEO: Mr. Bronson Crouch

Sector: Healthcare

Employees: 49

Address: 3963 Maple Avenue, Dallas, TX 75219

Phone: 972 499 3350

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation logo
Market Cap: Medium
Employees: Medium

immunoSEQ

Adaptive Biotechnologies Corporation is a commercial-stage company that develops an immune medicine platform for diagnosing and treating various diseases, including COVID-19 and lymphoid cancers.

Tags: COVID-19, cancer, diagnostics, immune medicine, immunosequencing, translational research

Symbol: ADPT

Recent Price: $6.11

Industry: Biotechnology

CEO: Mr. Chad M. Robins M.B.A.

Sector: Healthcare

Employees: 709

Address: 1165 Eastlake Avenue East, Seattle, WA 98109

Phone: 206 659 0067

Last updated: 2024-12-31